Arch Therapeutics, Inc. Logo

Arch Therapeutics, Inc.

ARTH

(1.8)
Stock Price

0,17 USD

-877.38% ROA

121.05% ROE

-0.17x PER

Market Cap.

2.044.406,00 USD

-128.1% DER

0% Yield

-8276.47% NPM

Arch Therapeutics, Inc. Stock Analysis

Arch Therapeutics, Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Arch Therapeutics, Inc. Fundamental Stock Analysis
# Analysis Rating
1 ROE

ROE surpassing expectations (122.5%) highlights strong profitability and efficient use of shareholders' equity, making it an appealing investment prospect.

2 PBV

The stock's low PBV ratio (-0.43x) suggests it's undervalued, making it an attractive opportunity for investors.

3 DER

The stock has a low debt to equity ratio (-39%), which means it has a small amount of debt compared to the ownership it holds

4 Graham Number

The Graham number calculation reveals that this company's stock price is potentially underestimated, implying that it may be a promising investment option.

5 ROA

The stock's ROA (-479.34%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

6 Revenue Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

7 Net Profit Growth

Over the past five years, this company's net profit has failed to exhibit any growth, indicating a stagnant financial performance and making it a less favorable choice for potential investors.

8 Assets Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

9 Dividend Growth

Potential investors should be aware that the company's dividend growth has shown no upward trend in the past three years, indicating limited potential for increased returns.

10 Dividend

No dividends from the company in the past three years raises doubts about its profitability for shareholders.

11 Buffet Intrinsic Value

Warren Buffett's formula suggests that the company's stock is overpriced (0), presenting a possible disadvantage for investors as its market price surpasses its estimated intrinsic value.

Arch Therapeutics, Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Arch Therapeutics, Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Buy
3 RSI Hold
4 Stoch RSI Hold

Arch Therapeutics, Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Arch Therapeutics, Inc. Revenue
Year Revenue Growth
2011 0
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 11.565 100%
2022 15.652 26.11%
2023 53.172 70.56%
2023 75.724 29.78%
2024 123.652 38.76%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Arch Therapeutics, Inc. Research and Development Expenses
Year Research and Development Expenses Growth
2011 0
2012 87.021 100%
2013 218.901 60.25%
2014 1.477.479 85.18%
2015 1.760.037 16.05%
2016 1.683.299 -4.56%
2017 2.094.795 19.64%
2018 2.884.245 27.37%
2019 2.396.838 -20.34%
2020 1.611.094 -48.77%
2021 1.353.084 -19.07%
2022 1.153.333 -17.32%
2023 556.192 -107.36%
2023 670.880 17.1%
2024 622.724 -7.73%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Arch Therapeutics, Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
2011 5.037
2012 36.611 86.24%
2013 1.526.075 97.6%
2014 3.134.285 51.31%
2015 3.700.477 15.3%
2016 4.367.476 15.27%
2017 5.207.753 16.14%
2018 4.565.522 -14.07%
2019 3.974.919 -14.86%
2020 3.759.554 -5.73%
2021 5.009.323 24.95%
2022 4.519.636 -10.83%
2023 0 0%
2023 4.371.164 100%
2024 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Arch Therapeutics, Inc. EBITDA
Year EBITDA Growth
2011 -5.037
2012 -36.611 86.24%
2013 -1.744.326 97.9%
2014 -4.611.442 62.17%
2015 -5.460.514 15.55%
2016 -6.050.775 9.76%
2017 -7.301.050 17.12%
2018 -7.444.425 1.93%
2019 -8.187.694 9.08%
2020 -6.042.993 -35.49%
2021 -6.196.308 2.47%
2022 -5.705.610 -8.6%
2023 -4.056.256 -40.66%
2023 -5.042.510 19.56%
2024 -4.084.396 -23.46%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Arch Therapeutics, Inc. Gross Profit
Year Gross Profit Growth
2011 0
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 -1.498 100%
2018 -5.342 71.96%
2019 -8.238 35.15%
2020 -6.926 -18.94%
2021 -14.717 52.94%
2022 -35.837 58.93%
2023 -20.944 -71.11%
2023 -2.439 -758.71%
2024 39.336 106.2%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Arch Therapeutics, Inc. Net Profit
Year Net Profit Growth
2011 -5.037
2012 -36.611 86.24%
2013 -1.853.791 98.03%
2014 -8.142.823 77.23%
2015 -2.947.526 -176.26%
2016 -5.992.370 50.81%
2017 -7.788.856 23.06%
2018 -4.814.032 -61.79%
2019 -2.723.407 -76.77%
2020 -4.012.106 32.12%
2021 -6.569.242 38.93%
2022 -4.275.854 -53.64%
2023 -7.292.428 41.37%
2023 -6.982.836 -4.43%
2024 -22.618.724 69.13%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Arch Therapeutics, Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2011 0
2012 -1 100%
2013 -17 94.12%
2014 -24 29.17%
2015 -7 -242.86%
2016 -10 22.22%
2017 -11 10%
2018 -6 -66.67%
2019 -3 -100%
2020 -4 25%
2021 -6 20%
2022 -4 -66.67%
2023 -6 40%
2023 -2 -150%
2024 -5 60%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Arch Therapeutics, Inc. Free Cashflow
Year Free Cashflow Growth
2011 -2.136
2012 -33.757 93.67%
2013 -1.336.332 97.47%
2014 -3.348.502 60.09%
2015 -4.239.386 21.01%
2016 -4.747.027 10.69%
2017 -5.624.934 15.61%
2018 -5.928.978 5.13%
2019 -5.268.302 -12.54%
2020 -5.047.210 -4.38%
2021 -5.961.903 15.34%
2022 -4.456.075 -33.79%
2023 -897.549 -396.47%
2023 -3.378.737 73.44%
2024 -911.641 -270.62%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Arch Therapeutics, Inc. Operating Cashflow
Year Operating Cashflow Growth
2011 -2.136
2012 -33.757 93.67%
2013 -1.336.332 97.47%
2014 -3.348.502 60.09%
2015 -4.239.386 21.01%
2016 -4.747.027 10.69%
2017 -5.616.248 15.48%
2018 -5.913.563 5.03%
2019 -5.268.302 -12.25%
2020 -5.044.755 -4.43%
2021 -5.958.628 15.34%
2022 -4.456.075 -33.72%
2023 -897.549 -396.47%
2023 -3.374.216 73.4%
2024 -911.641 -270.13%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Arch Therapeutics, Inc. Capital Expenditure
Year Capital Expenditure Growth
2011 0
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 8.686 100%
2018 15.415 43.65%
2019 0 0%
2020 2.455 100%
2021 3.275 25.04%
2022 0 0%
2023 0 0%
2023 4.521 100%
2024 0 0%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Arch Therapeutics, Inc. Equity
Year Equity Growth
2011 14.963
2012 -1.348 1210.01%
2013 187.016 100.72%
2014 -6.892.443 102.71%
2015 1.540.117 547.53%
2016 3.160.995 51.28%
2017 2.226.519 -41.97%
2018 1.359.828 -63.74%
2019 -807.297 268.44%
2020 -1.500.491 46.2%
2021 -1.025.674 -46.29%
2022 -4.192.803 75.54%
2023 -8.015.028 47.69%
2023 -7.507.732 -6.76%
2024 -12.560.566 40.23%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Arch Therapeutics, Inc. Assets
Year Assets Growth
2011 18.024
2012 4.718 -282.03%
2013 1.587.332 99.7%
2014 876.990 -81%
2015 4.003.019 78.09%
2016 5.144.260 22.18%
2017 6.090.083 15.53%
2018 4.839.965 -25.83%
2019 2.902.204 -66.77%
2020 2.151.027 -34.92%
2021 3.676.485 41.49%
2022 2.603.739 -41.2%
2023 1.564.246 -66.45%
2023 1.958.189 20.12%
2024 1.397.644 -40.11%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Arch Therapeutics, Inc. Liabilities
Year Liabilities Growth
2011 3.061
2012 6.066 49.54%
2013 1.400.316 99.57%
2014 7.769.433 81.98%
2015 2.462.902 -215.46%
2016 1.983.265 -24.18%
2017 3.863.564 48.67%
2018 3.480.137 -11.02%
2019 3.709.501 6.18%
2020 3.651.518 -1.59%
2021 4.702.159 22.34%
2022 6.796.542 30.82%
2023 9.579.274 29.05%
2023 9.465.921 -1.2%
2024 13.958.210 32.18%

Arch Therapeutics, Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0.03
Net Income per Share
-2.76
Price to Earning Ratio
-0.17x
Price To Sales Ratio
13.8x
POCF Ratio
-0.55
PFCF Ratio
-0.55
Price to Book Ratio
-0.16
EV to Sales
76.96
EV Over EBITDA
-2.42
EV to Operating CashFlow
-3.08
EV to FreeCashFlow
-3.08
Earnings Yield
-6
FreeCashFlow Yield
-1.81
Market Cap
0,00 Bil.
Enterprise Value
0,01 Bil.
Graham Number
13.25
Graham NetNet
-2.99

Income Statement Metrics

Net Income per Share
-2.76
Income Quality
0.3
ROE
1.21
Return On Assets
-8.77
Return On Capital Employed
0.38
Net Income per EBT
1
EBT Per Ebit
2.6
Ebit per Revenue
-31.87
Effective Tax Rate
0.13

Margins

Sales, General, & Administrative to Revenue
21.19
Research & Developement to Revenue
5.16
Stock Based Compensation to Revenue
0.46
Gross Profit Margin
0.4
Operating Profit Margin
-31.87
Pretax Profit Margin
-82.76
Net Profit Margin
-82.76

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0.83
Free CashFlow per Share
-0.83
Capex to Operating CashFlow
-0
Capex to Revenue
0.03
Capex to Depreciation
2.02
Return on Invested Capital
-1.17
Return on Tangible Assets
-8.77
Days Sales Outstanding
0
Days Payables Outstanding
11891.95
Days of Inventory on Hand
5383.1
Receivables Turnover
0
Payables Turnover
0.03
Inventory Turnover
0.07
Capex per Share
0

Balance Sheet

Cash per Share
0,01
Book Value per Share
-2,83
Tangible Book Value per Share
-2.83
Shareholders Equity per Share
-2.83
Interest Debt per Share
4.43
Debt to Equity
-1.28
Debt to Assets
11.51
Net Debt to EBITDA
-1.98
Current Ratio
0.1
Tangible Asset Value
-0,01 Bil.
Net Current Asset Value
-0,01 Bil.
Invested Capital
-12564066
Working Capital
-0,01 Bil.
Intangibles to Total Assets
0
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
1324934.5
Debt to Market Cap
7.87

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Arch Therapeutics, Inc. Dividends
Year Dividends Growth

Arch Therapeutics, Inc. Profile

About Arch Therapeutics, Inc.

Arch Therapeutics, Inc., together with its subsidiaries, operates as a biotechnology company in the United States. The company develops and markets products based on its AC5 self-assembling technology platform to stop bleeding and control leaking, as well as manages wounds during surgery, trauma, and interventional care or from disease. Its flagship products include AC5 advanced wound system and AC5 topical hemostat, which are intended for skin applications, such as management of complicated chronic wounds or acute surgical wounds. The company was founded in 2006 and is based in Framingham, Massachusetts.

CEO
Dr. Terrence W. Norchi M.D.
Employee
8
Address
235 Walnut Street
Framingham, 01702

Arch Therapeutics, Inc. Executives & BODs

Arch Therapeutics, Inc. Executives & BODs
# Name Age
1 Dr. Terrence W. Norchi M.D.
Co-Founder, Chairman, President & Chief Executive Officer
70
2 Mr. Shawn Carlson
Vice President of Sales
70
3 Mr. Michael S. Abrams
Chief Financial Officer & Treasurer
70
4 Dr. Rutledge Ellis-Behnke Ph.D.
Co-Founder & Scientific Advisor
70

Arch Therapeutics, Inc. Competitors